Navigation Links
BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
Date:2/1/2011

NOVATO, Calif., Feb. 1, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.  

"In under two years, we have progressed the GALNS program from Clinical Trial Application to initiation of the Phase 3 trial.  We have received FDA feedback and have finalized the design of the Phase 3 pivotal trial," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "The study will be conducted at approximately 40 centers worldwide including Brazil, Japan, Taiwan, most Western European countries, Canada and the U.S.  The trial is expected to enroll approximately 160 subjects and will be the largest enzyme replacement therapy trial conducted. There are no therapeutic options for MPS IVA patients who have a high unmet medical need. Initiation of this well-designed pivotal study is an important milestone for both the company and the MPS IVA community."

The Phase 3 trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GALNS in patients with MPS IVA.  The study will explore doses of two mg/kg/week and two mg/kg/every other week for a treatment period of 24 weeks.  The primary endpoint is the six-minute walk test, and the secondary endpoints are the three-minute stair climb test and urine keratan sulfate concentration.  

About MPS IVMucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disease characterized by deficient activity of N-acetylgalactosamine 6-sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature,
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... by all subjects and sustained levels of drug ... Potentia Pharmaceuticals, a privately held biotechnology company developing ... (AMD), announced today that it successfully completed its ... POT-4 Therapy for Patients with Neovascular Age-Related Macular ...
... $55 Million in Near Term Payments -CAMBRIDGE, Mass., ... that the company has entered into an out-licensing ... to develop and commercialize the investigational compound linaclotide ... constipation (IBS-C) and other gastrointestinal conditions. This agreement ...
Cached Medicine Technology:Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II 2Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II 3Ironwood Announces Linaclotide European Licensing Agreement with Almirall 2Ironwood Announces Linaclotide European Licensing Agreement with Almirall 3
(Date:12/21/2014)... Concept Plus, LLC. a SDB and ... Fairfax, VA., today announced it has been recognized by ... which ranks the fastest growing government contracting small businesses by ... , This is the first year that Concept Plus, LLC., ... with a 95.92% compound annual growth rate. “For Concept Plus ...
(Date:12/20/2014)... a distinguished special dress supplier, has just done something ... cut prices to all its prom dresses already, offering ... Many of the hottest styles are sold here like ... more. , A spokesman for MissyDress says, “The great ... prom dresses or sweetheart chiffon prom dresses, you will ...
(Date:12/20/2014)... LunaDress has recently announced its 2015 collection of ... on all of its special occasion dresses & wedding apparel. ... wedding gown. If you have no idea of what to ... different wedding dress styles and our dress experts are here ... current special offer, up to 80% off," the CEO of ...
(Date:12/20/2014)... SATURDAY, Dec. 20, 2014 (HealthDay News) -- The holidays ... when they contend with fresh trees, scented candles and ... and on the decorations that have been packed away ... in my allergy and asthma patients," Dr. Rachna Shah, ... School of Medicine, said in Loyola news release. ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and retailer, ... The company has recently updated its official blog with ... season, Angeldress Blog has recommended some new ... prides itself in offering a huge selection of elegant ... company’s outfits are very carefully selected based on the ...
Breaking Medicine News(10 mins):Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2
... A review and analysis of previously published studies finds ... relationships between medicine and industry should be disclosed, in ... clinical care, according to a report in the April ... one of the JAMA/Archives journals. "Financial ties to ...
... development of screening tests for early detection , MONDAY, April ... of ovarian cancer may lead to the development of a ... In the study, scientists uncovered early tumors and precancerous lesions ... surface. , "This is the first study giving very strong ...
... fruits and veggies die earlier than usual, study finds , ... unhealthy behaviors -- smoking, lack of exercise, poor diet and ... death, a new study has found. , The study, published ... Medicine , included 4,886 people, aged 18 or older, who ...
... (ASTRO) applauds President Obama,s selection of Donald Berwick, M.D., ... Medicare and Medicaid Services. ASTRO looks forward to working ... implement critical healthcare reforms for patients and work toward ... the quality of care patients receive. ASTRO,s highest priority ...
... Lisa P. Jackson and NASA Administrator Charles Bolden ... education at the Howard University Middle School of ... chose the Howard University Middle School to underscore ... the next generation of leaders. The administrators also ...
... researchers say , MONDAY, April 26 (HealthDay News) -- It ... for colon cancer, a new study suggests. , Researchers analyzed ... cancer-free people. They identified unusual levels of 16 substances in ... tryptophan, one of the 22 amino acids found in proteins. ...
Cached Medicine News:Health News:Patients, clinicians favor disclosure of financial ties to industry 2Health News:Patients, clinicians favor disclosure of financial ties to industry 3Health News:Study Makes Strides in Understanding Ovarian Cancer 2Health News:Four Unhealthy Behaviors Linked to Premature Death 2Health News:EPA and NASA administrators to extend environmental and Earth science agreement 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: